301,402 Shares in Pfizer Inc. $PFE Purchased by Contravisory Investment Management Inc.

Contravisory Investment Management Inc. bought a new position in Pfizer Inc. (NYSE:PFE) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 301,402 shares of the biopharmaceutical company’s stock, valued at approximately $8,463,000. Pfizer comprises about 1.7% of Contravisory Investment Management Inc.’s investment portfolio, making the stock its 24th largest position.

Other hedge funds also recently made changes to their positions in the company. Vermillion Wealth Management Inc. boosted its stake in Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 382 shares during the period. Triad Wealth Partners LLC grew its stake in Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 386 shares in the last quarter. Eagle Capital Management LLC increased its holdings in Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after buying an additional 390 shares during the last quarter. ETF Store Inc. lifted its stake in shares of Pfizer by 3.8% in the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 396 shares during the last quarter. Finally, Mattern Wealth Management LLC lifted its position in shares of Pfizer by 4.6% in the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after buying an additional 400 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 1.7%

NYSE PFE opened at $23.64 on Friday. The stock’s 50 day simple moving average is $26.00 and its 200 day simple moving average is $26.30. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The firm has a market cap of $134.71 billion, a PE ratio of 18.04 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same quarter in the previous year, the firm earned $0.92 earnings per share. The business’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.3%. Pfizer’s payout ratio is currently 131.30%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on PFE shares. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research report on Tuesday. CICC Research began coverage on Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective for the company. Cantor Fitzgerald reissued a “neutral” rating on shares of Pfizer in a report on Monday, June 1st. Finally, Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research note on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $28.82.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded Ibrance for frontline maintenance use in HR-positive, HER2-positive advanced or metastatic breast cancer, giving Pfizer a new label expansion that could support sales and help offset pressure from older drugs. FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
• Positive Sentiment: Pfizer announced its quarterly dividend remains at $0.43 per share, reinforcing the company’s shareholder-return profile and highlighting management’s commitment to its payout. Pfizer Declares Third-Quarter 2026 Dividend
• Positive Sentiment: Pfizer was dismissed from a U.S. states’ generic drug price-fixing lawsuit, removing a potential legal overhang. Pfizer dismissed from US states’ drug price-fixing lawsuit
• Neutral Sentiment: Pfizer Ventures helped lead a $62 million Series B for Oblenio Bio, showing continued investment in early-stage biotech opportunities, though the deal is unlikely to move the stock near term. Oblenio Bio Closes $62 Million Series B
• Negative Sentiment: Earlier reports said Pfizer’s Phase 3 lung cancer data for sigvotatug vedotin failed to show a statistically significant overall survival benefit, fueling concerns about its long-term oncology pipeline and helping explain the recent weakness in PFE. Pfizer (PFE) Is Down 7.3% After Mixed Oncology Updates Reshape Its Long-Term Pipeline Narrative
• Negative Sentiment: Comparison pieces weighing AbbVie versus Pfizer and Lilly versus Pfizer suggest investors still see Pfizer as the slower-growth big pharma name relative to peers, which can keep valuation pressure on the stock. AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.